Works matching AU de Haas, Sanne

Results: 16

89Zr-Bevacizumab PET Visualizes Heterogeneous Tracer Accumulation in Tumor Lesions of Renal Cell Carcinoma Patients and Differential Effects of Antiangiogenic Treatment.

Published in:

Journal of Nuclear Medicine, 2015, v. 56, n. 1, p. 63, doi. 10.2967/jnumed.114.144840

By:

Oosting, Sjoukje F.;
Brouwers, Adrienne H.;
van Es, Suzanne C.;
Nagengast, Wouter B.;
Munnink, Thijs H. Oude;
Lub-de Hooge, Marjolijn N.;
Hollema, Harry;
de Jong, Johan R.;
de Jong, Igle J.;
de Haas, Sanne;
Scherer, Stefan J.;
Sluiter, Wim J.;
Dierckx, Rudi A.;
Bongaerts, Alfons H. H.;
Gietema, Jourik A.;
de Vries, Elisabeth G. E.

Publication type:

Article

An Overview of the CNS-Pharmacodynamic Profiles of Nonselective and Selective GABA Agonists.

Published in:

Advances in Pharmacological Sciences, 2012, v. 2012, p. 1, doi. 10.1155/2012/134523

By:

Xia Chen;
de Haas, Sanne;
de Kam, Marieke;
van Gerven, Joop

Publication type:

Article

Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE.

Published in:

NPJ Breast Cancer, 2022, v. 8, n. 1, p. 1, doi. 10.1038/s41523-022-00477-z

By:

Loibl, Sibylle;
Huang, Chiun-Sheng;
Mano, Max S.;
Mamounas, Eleftherios P.;
Geyer Jr, Charles E.;
Untch, Michael;
Thery, Jean-Christophe;
Schwaner, Ingo;
Limentani, Steven;
Loman, Niklas;
Lübbe, Kristina;
Chang, Jenny C.;
Hatschek, Thomas;
Tesarowski, David;
Song, Chunyan;
Lysbet de Haas, Sanne;
Boulet, Thomas;
Lambertini, Chiara;
Wolmark, Norman

Publication type:

Article

High plasma concentrations of human urotensin II do not alter local or systemic hemodynamics in man

Published in:

Cardiovascular Research, 2002, v. 53, n. 2, p. 341, doi. 10.1016/S0008-6363(01)00485-0

By:

Wilkinson, Ian B.;
Affolter, Jonathan T.;
de Haas, Sanne L.;
Paola Pellegrini, M.;
Boyd, Judith;
Winter, Matthew J.;
Balment, Richard J.;
Webb, David J.

Publication type:

Article

Effect of an NK1/NK2 Receptor Antagonist on Airway Responses and Inflammation to Allergen in Asthma.

Published in:

American Journal of Respiratory & Critical Care Medicine, 2007, v. 175, n. 5, p. 450, doi. 10.1164/rccm.200608-1186OC

By:

Boot, Johan D.;
de Haas, Sanne;
Tarasevych, Svetlana;
Roy, Christine;
Wang, Lin;
Amin, Dilip;
Cohen, Judith;
Sterk, Peter J.;
Miller, Barry;
Paccaly, Anne;
Burggraaf, Jacobus;
Cohen, Adam F.;
Diamant, Zuzana

Publication type:

Article

Correction to: Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer.

Published in:

2019

By:

Perez, Edith A.;
de Haas, Sanne Lysbet;
Eiermann, Wolfgang;
Barrios, Carlos H.;
Toi, Masakazu;
Im, Young-Hyuck;
Conte, Pier Franco;
Martin, Miguel;
Pienkowski, Tadeusz;
Pivot, Xavier B.;
Burris III, Howard A.;
Stanzel, Sven;
Patre, Monika;
Ellis, Paul Anthony;
Burris, Howard A 3rd

Publication type:

journal article

Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer.

Published in:

2019

By:

Perez, Edith A.;
de Haas, Sanne Lysbet;
Eiermann, Wolfgang;
Barrios, Carlos H.;
Toi, Masakazu;
Im, Young-Hyuck;
Conte, Pier Franco;
Martin, Miguel;
Pienkowski, Tadeusz;
Pivot, Xavier B.;
Burris III, Howard A.;
Stanzel, Sven;
Patre, Monika;
Ellis, Paul Anthony;
Burris, Howard A 3rd

Publication type:

journal article

Relationship between tumor biomarkers and efficacy in TH3RESA, a phase III study of trastuzumab emtansine (T-DM1) vs. treatment of physician's choice in previously treated HER2-positive advanced breast cancer.

Published in:

International Journal of Cancer, 2016, v. 139, n. 10, p. 2336, doi. 10.1002/ijc.30276

By:

Kim, Sung‐Bae;
Wildiers, Hans;
Krop, Ian E.;
Smitt, Melanie;
Yu, Ron;
Lysbet de Haas, Sanne;
Gonzalez‐Martin, Antonio

Publication type:

Article

Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2-positive advanced breast cancer: Final results from MARIANNE.

Published in:

2019

By:

Perez, Edith A.;
Barrios, Carlos;
Eiermann, Wolfgang;
Toi, Masakazu;
Im, Young‐Hyuck;
Conte, Pierfranco;
Martin, Miguel;
Pienkowski, Tadeusz;
Pivot, Xavier B.;
Burris, Howard A.;
Petersen, Jennifer A.;
De Haas, Sanne;
Hoersch, Silke;
Patre, Monika;
Ellis, Paul Anthony;
Im, Young-Hyuck;
Burris, Howard A 3rd

Publication type:

journal article

Biomarker analysis of the GATSBY study of trastuzumab emtansine versus a taxane in previously treated HER2-positive advanced gastric/gastroesophageal junction cancer.

Published in:

Gastric Cancer, 2019, v. 22, n. 4, p. 803, doi. 10.1007/s10120-018-00923-7

By:

Shah, Manish A.;
Kang, Yoon-Koo;
Thuss-Patience, Peter C.;
Ohtsu, Atsushi;
Ajani, Jaffer A.;
Van Cutsem, Eric;
Hoersch, Silke;
Harle-Yge, Marie-Laurence;
de Haas, Sanne Lysbet

Publication type:

Article

BERENICE Final Analysis: Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab in HER2-Positive Early Breast Cancer.

Published in:

Cancers, 2022, v. 14, n. 11, p. 2596, doi. 10.3390/cancers14112596

By:

Dang, Chau;
Ewer, Michael S.;
Delaloge, Suzette;
Ferrero, Jean-Marc;
Colomer, Ramon;
de la Cruz-Merino, Luis;
Werner, Theresa L.;
Dadswell, Katherine;
Verrill, Mark;
Eiger, Daniel;
Sarkar, Sriparna;
de Haas, Sanne Lysbet;
Restuccia, Eleonora;
Swain, Sandra M.

Publication type:

Article

Immune Markers and Tumor-Related Processes Predict Neoadjuvant Therapy Response in the WSG-ADAPT HER2-Positive/Hormone Receptor-Positive Trial in Early Breast Cancer.

Published in:

Cancers, 2021, v. 13, n. 19, p. 4884, doi. 10.3390/cancers13194884

By:

Harbeck, Nadia;
von Schumann, Raquel;
Kates, Ronald Ernest;
Braun, Michael;
Kuemmel, Sherko;
Schumacher, Claudia;
Potenberg, Jochem;
Malter, Wolfram;
Augustin, Doris;
Aktas, Bahriye;
Forstbauer, Helmut;
Tio, Joke;
Grischke, Eva-Maria;
Biehl, Claudia;
Liedtke, Cornelia;
De Haas, Sanne Lysbet;
Deurloo, Regula;
Wuerstlein, Rachel;
Kreipe, Hans Heinrich;
Gluz, Oleg

Publication type:

Article

Promotion of sleep by targeting the orexin system in rats, dogs and humans.

Published in:

Nature Medicine, 2007, v. 13, n. 2, p. 150, doi. 10.1038/nm1544

By:

Brisbare-Roch, Catherine;
Dingemanse, Jasper;
Koberstein, Ralf;
Hoever, Petra;
Aissaoui, Hamed;
Flores, Susan;
Mueller, Celia;
Nayler, Oliver;
van Gerven, Joop;
de Haas, Sanne L;
Hess, Patrick;
Qiu, Changbin;
Buchmann, Stephan;
Scherz, Michael;
Weller, Thomas;
Fischli, Walter;
Clozel, Martine;
Jenck, François

Publication type:

Article

Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine + pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III study (KRISTINE).

Published in:

Breast Cancer Research, 2023, v. 25, n. 1, p. 1, doi. 10.1186/s13058-022-01587-z

By:

de Haas, Sanne L.;
Slamon, Dennis J.;
Martin, Miguel;
Press, Michael F.;
Lewis, Gail D.;
Lambertini, Chiara;
Prat, Aleix;
Lopez-Valverde, Vanesa;
Boulet, Thomas;
Hurvitz, Sara A.

Publication type:

Article

Orexin receptor antagonism: an ascending multiple-dose study with almorexant.

Published in:

Journal of Psychopharmacology, 2012, v. 26, n. 8, p. 1071, doi. 10.1177/0269881112448946

By:

Hoever, Petra;
de Haas, Sanne L;
Dorffner, Georg;
Chiossi, Eleonora;
van Gerven, Joop M;
Dingemanse, Jasper

Publication type:

Article

Subjective Sleep Disturbance in Patients with Partial Epilepsy: A Questionnaire-based Study on Prevalence and Impact on Quality of Life.

Published in:

Epilepsia (Series 4), 2004, v. 45, n. 11, p. 1397, doi. 10.1111/j.0013-9580.2004.46703.x

By:

de Weerd, Al;
de Haas, Sanne;
Otte, Andreas;
Trenité, Dorothée Kasteleijn-Nolst;
van Erp, Gerard;
Cohen, Adam;
de Kam, Marieke;
van Gerven, Joop

Publication type:

Article

Works matching AU de Haas, Sanne

<sup>89</sup>Zr-Bevacizumab PET Visualizes Heterogeneous Tracer Accumulation in Tumor Lesions of Renal Cell Carcinoma Patients and Differential Effects of Antiangiogenic Treatment.

An Overview of the CNS-Pharmacodynamic Profiles of Nonselective and Selective GABA Agonists.

Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE.

High plasma concentrations of human urotensin II do not alter local or systemic hemodynamics in man

Effect of an NK<sub>1</sub>/NK<sub>2</sub> Receptor Antagonist on Airway Responses and Inflammation to Allergen in Asthma.

Correction to: Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer.

Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer.

Relationship between tumor biomarkers and efficacy in TH3RESA, a phase III study of trastuzumab emtansine (T-DM1) vs. treatment of physician's choice in previously treated HER2-positive advanced breast cancer.

Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2-positive advanced breast cancer: Final results from MARIANNE.

Biomarker analysis of the GATSBY study of trastuzumab emtansine versus a taxane in previously treated HER2-positive advanced gastric/gastroesophageal junction cancer.

BERENICE Final Analysis: Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab in HER2-Positive Early Breast Cancer.

Immune Markers and Tumor-Related Processes Predict Neoadjuvant Therapy Response in the WSG-ADAPT HER2-Positive/Hormone Receptor-Positive Trial in Early Breast Cancer.

Promotion of sleep by targeting the orexin system in rats, dogs and humans.

Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine + pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III study (KRISTINE).

Orexin receptor antagonism: an ascending multiple-dose study with almorexant.

Subjective Sleep Disturbance in Patients with Partial Epilepsy: A Questionnaire-based Study on Prevalence and Impact on Quality of Life.